Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic s Revenues Up in Q4; Boehringer Ingelheim Renews License

Please click here for an updated version of this article.

 

NEW YORK, Feb. 20 (GenomeWeb News) - Gene Logic reported increased revenues and slightly narrowed losses for the fourth quarter of 2003.

 

Revenues for the quarter increased to $19.7 million, up from $14.8 million during the same period in 2002.

 

R&D costs decreased to $.5 million, from $.8 million during the same quarter a year ago.

 

The company's net loss decreased slightly to $4.9 million, or $.16 per share, from $5.2 million, or $.19 per share, during the fourth quarter a year ago.

 

As of Dec. 31, Gene Logic had approximately $111.8 million in cash, cash equivalents and marketable securities available-for-sale. This includes $48.7 million in cash and cash equivalents.

 

Click here for the full earnings report.

 

Separately, Gene Logic said that Boehringer Ingelheim has renewed its license to Gene Logic's GeneExpress information services for several years.

 

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.